DCAT’s 2025 Study: 
What Makes a Customer of Choice: Are Pharma Companies & Suppliers Aligned?

About the Study

Strong and mutually beneficial supplier relations are always of crucial importance to bio/pharma companies and their suppliers, but those relationships have taken on even greater importance as companies navigate unique challenges to assure supply of critical materials and services.

With greater reliance on suppliers, bio/pharma companies are more aware of how their supplier relationships can impact their ability to deliver value to key stakeholders: patients and investors.

To provide DCAT Member Companies further insight into this evolving customer–supplier dynamic, and to benchmark their own journey it, DCAT’s 2025 study examines what initiatives companies are making to becoming Preferred Customers of their suppliers, how suppliers designate those “Customers of Choice,” the benefits accrued, and whether the expectations of customers and suppliers are aligned.